Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• N-22 Humeral Head Cleared & Launched: Shoulder Innovations, Inc. received FDA 510(k) clearance and initiated the commercial launch of its titanium N-22 Humeral Head, providing a complete metal-sensitive implant solution across anatomic and reverse shoulder arthroplasty.
• 350,000 OsteoSync® Ti Implantations Milestone: SITES Medical surpassed 350,000 global implantations of its porous titanium ingrowth platform across 15 OEM partners in spine, joint reconstruction, and extremities.
• AAOS Warns Against Proposed CMS Payment Cuts: The American Academy of Orthopaedic Surgeons (AAOS) cautioned that proposed 2027 CMS Medicare conversion factor reductions and practice-expense cuts threaten orthopaedic practice viability and surgical access.
• Zimmer Biomet OSS™ OsseoTi® Sleeves Cleared: Biomet Orthopedics, Inc. secured FDA 510(k) clearance (K253515) for OSS™ Orthopedic Salvage System OsseoTi® sleeves and augments for limb salvage and complex revision arthroplasty.
• TiLink-L™ SI Joint Fusion System Cleared: SurGenTec, LLC received FDA 510(k) clearance (K261381) for its TiLink-L™ minimally invasive sacroiliac joint fusion and fixation system.

DAILY ANNOUNCEMENTS BY CATEGORY

Joint Reconstruction

Shoulder Innovations, Inc. — FDA 510(k) Clearance and Commercial Launch for N-22 Humeral Head

• Summary: Shoulder Innovations announced it has received FDA 510(k) clearance and initiated full commercial launch for its N-22 Humeral Head, an engineered titanium implant designed for patients with metal hypersensitivity. The implant complements the previously cleared N-22 Glenosphere, providing orthopaedic surgeons with a complete metal-sensitive option across both anatomic and reverse shoulder arthroplasty configurations.
• Key Details:
  • Device/System Name: N-22 Humeral Head System
  • Status: FDA 510(k) Cleared & Full Commercial Launch
  • Clinical Significance: Provides an engineered titanium humeral component specifically designed for patients with metal hypersensitivity undergoing anatomic total shoulder arthroplasty, addressing allergic concerns in 10% to 15% of the population and complementing the N-22 Glenosphere for complete procedural versatility.
• Original Source: OrthoSpineNews

Spine & Orthobiologics

SITES Medical — Milestone of 350,000 OsteoSync® Ti Implantations Worldwide Across OEM Partnerships

• Summary: SITES Medical announced the milestone of more than 350,000 OsteoSync® Ti implants placed globally across more than a decade of clinical use. The porous, commercially pure titanium technology platform has been adopted by 15 orthopaedic OEM partners across spine, total joint reconstruction, and extremity indications.
• Key Details:
  • Device/System Name: OsteoSync® Ti Porous Titanium Ingrowth Platform
  • Status: Commercial & Clinical Milestone (15 OEM Partners)
  • Clinical Significance: Provides longitudinal real-world validation of highly porous additive/engineered titanium scaffolds for bone ingrowth, supporting stable osseointegration and reducing revision risks from aseptic loosening across high-load joint and spinal applications.
• Original Source: BONEZONE

Corporate, M&A & Regulatory

American Academy of Orthopaedic Surgeons (AAOS) — AAOS Leadership Warns Proposed CMS 2027 Payment Cuts Threaten Orthopaedic Care Delivery

• Summary: AAOS leadership highlighted the acute risks posed by the Centers for Medicare & Medicaid Services' (CMS) proposed 2027 Medicare Physician Fee Schedule, which introduces further conversion factor reductions and practice-expense payment adjustments. AAOS President Dr. Wilford K. Gibson emphasized that unmitigated reimbursement cuts undermine the financial viability of orthopaedic practices and patient access to timely surgical care.
• Key Details:
  • Device/System Name: CY 2027 Medicare Physician Fee Schedule Regulatory Response
  • Status: Healthcare Policy & Clinical Governance
  • Clinical Significance: Underscores mounting economic and operational pressures on orthopaedic surgical practices, highlighting AAOS advocacy for comprehensive statutory payment reform to ensure sustainable patient access to musculoskeletal surgery.
• Original Source: Orthopedics This Week

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES — ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2–4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.